News

Pharmaceutical Technology43m
AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancer
The approval comes amid speculation that AstraZeneca CEO Pascal Soriot is considering delisting its UK stock market listing for the US.
FTSE 100 movers: AstraZeneca gains; Barratt hit by MJ Gleeson update
London’s FTSE 100 was flat at 8,824.61 in quiet afternoon trade on Friday, with US markets closed for Independence Day.
Why AstraZeneca Stock Got Thumped on Thursday
It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...
AstraZeneca considers moving listing to US, the Times reports
AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...
AstraZeneca CEO Wants to Move Listing to US, Times Reports
AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...
The Pharma Letter5h
AstraZeneca gets EU approval for Imfinzi combo in early bladder cancer
British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...
AstraZeneca's Imfinzi gets EU green light
Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative ...
AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment
AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...